Jack Sloane
Senior Principal Scientist Bristol Myers Squibb
Jack L. Sloane, Ph.D. is a Principal Scientist at Bristol Myers Squibb with 7 years of experience in small molecule drug discovery across oncology and immunology. He holds a Ph.D. in Organic Chemistry from Stanford University and a B.A. with Honors from Johns Hopkins University. At BMS, Jack has led hit-to-lead chemistry for 9 programs, discovering novel ligands for previously undruggable targets and developing deep expertise in phenotypic screening and hit deconvolution. He has contributed to multiple full-phase programs, delivering development candidates and in vivo tool molecules. He currently leads oncology efforts against novel targets, employing diverse modalities including degraders, covalent inhibitors, and heterobifunctional molecules. He is a co-author on 17 peer-reviewed publications and holds 6 patents.
Seminars
- Exploring a “warhead-first” approach to covalent inhibitor design beyond traditional binder optimization strategies
- Leveraging novel reactive chemistries and molecular trajectories to uniquely engage on-form KRAS G12C selectivity
- Linker geometry, electrophilicity and heterocycle basicity jointly govern covalent potency against on-form KRAS G12C
